Information de reference pour ce titreAccession Number: | 00002300-200310000-00002.
|
Author: | HULL, S. P. MACDONALD; WOOD, M. L. *; HUTCHINSON, P. E. +; SLADDEN, M. +; MESSENGER, A. G. ++
|
Institution: | Pontefract General Infirmary, Pontefract WF8 1PL, U.K. (HULL) (*)Rotherham District General Hospital, Rotherham S60 2UD, U.K. +Leicester Royal Infirmary, Leicester LE1 SWW, U.K. ++Royal Hallamshire Hospital, Sheffield S10 2JF, U.K.
|
Title: | |
Source: | British Journal of Dermatology. 149(4):692-699, October 2003.
|
Abstract: | Summary: These guidelines for management of alopecia areata have been prepared for dermatologists on behalf of the British Association of Dermatologists. They present evidence-based guidance for treatment, with identification of the strength of evidence available at the time of preparation of the guidelines, and a brief overview of epidemiological aspects, diagnosis and investigation.
(C) 2003 British Association of Dermatologists
|
References: | 1 Walker SA, Rothman S. Alopecia areata: a statistical study and consideration of endocrine influences. J Invest Dermatol 1950; 14: 403-13.
2 Gip L, Lodin A, Molin L. Alopecia areata. A follow-up investigation of outpatient material. Acta Derm Venereol (Stockh) 1969; 49: 180-8.
3 Ikeda T. A new classification of alopecia areata. Dermatologica 1965; 131: 421-45.
4 Anderson I. Alopecia areata: a clinical study. Br Med J 1950; ii: 1250-2.
5 Muller SA, Winkelmann RK. Alopecia areata. Arch Dermatol 1963; 88: 290-7.
6 De Waard-van der Spek FB, Oranje AP, De Raeymaecker DM et al. Juvenile versus maturity-onset alopecia areata-a comparative retrospective clinical study. Clin Exp Dermatol 1989; 14: 429-33.
7 Sharma VK, Muralidhar S. Treatment of widespread alopecia areata in young patients with monthly oral corticosteroid pulse. Pediatr Dermatol 1998; 15: 313-17.
8 McDonagh AJG, Messenger AG. The pathogenesis of alopecia areata. Dermatol Clin 1996; 14: 661-70.
9 Gilhar A, Ullmann Y, Berkutzki T et al. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 1998; 101: 62-7.
10 Charuwichitratana S, Wattanakrai P, Tanrattanakorn S. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 2000; 136: 1276-7.
11 Pascher F, Kurtin S, Andrade E. Assay of 0.2% fluocinolone acetonide cream for alopecia areata and totalis. Dermatologica 1970; 141: 193-202.
12 Leyden JL, Kligman AM. Treatment of alopecia areata with steroid solution. Arch Dermatol 1972; 106: 924.
13 Porter D, Burton JL. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971; 85: 272-3.
14 Kubeyinje EP. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J 1994; 71: 674-5.
15 Abell E, Munro DD. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1973; 88: 55-9.
16 Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000; 11: 478-83.
17 Downs AM, Lear JT, Kennedy CT. Anaphylaxis to intradermal triamcinolone acetonide. Arch Dermatol 1998; 134: 1163-4 (Letter).
18 Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128: 1467-73.
19 Winter RJ, Kern F, Blizzard RM. Prednisone therapy for alopecia areata. A follow-up report. Arch Dermatol 1976; 112: 1549-52.
20 Burton JL, Shuster S. Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol (Stockh) 1975; 55: 493-6.
21 Friedli A, Labarthe MP, Engelhardt E et al. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 1998; 39: 597-602.
22 Perriard-Wolfensberger J, Pasche-Koo F, Mainetti C et al. Pulse of methylprednisolone in alopecia areata. Dermatology 1993; 187: 282-5.
23 Sharma VK. Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol 1996; 35: 133-6.
24 Sharma VK, Gupta S. Twice weekly 5 mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J Dermatol 1999; 26: 562-5.
25 Rosenberg EW, Drake L. In discussion of Dunaway DA. Alopecia areata. Arch Dermatol 1976; 112: 256.
26 Summer KH, Goggelmann W. 1-chloro-2,4-dinitrobenzene depletes glutathione in rat skin and is mutagenic in Salmonella typhimurium. Mutat Res 1980; 77: 91-3.
27 Wilkerson MG, Connor TH, Henkin J et al. Assessment of diphenylcyclopropenone for photochemically induced mutagenicity in the Ames assay. J Am Acad Dermatol 1987; 17: 606-11.
28 Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol (Stockh) 1983; 63: 49-52.
29 Rokhsar CK, Shupack JL, Vafai JJ et al. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol 1998; 39: 751-61.
30 van der Steen PH, Baar HM, Happle R et al. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991; 24: 227-30.
31 Gordon PM, Aldrige RD, McVittie E et al. Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months' follow-up. Br J Dermatol 1996; 134: 869-71.
32 Wiseman MC, Shapiro J, MacDonald N et al. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001; 137: 1063-8.
33 MacDonald Hull SP, Pepall L, Cunliffe WJ. Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol 1991; 125: 164-8.
34 Schuttelaar ML, Hamstra JJ, Plinck EP et al. Alopecia areata in children: treatment with diphencyprone. Br J Dermatol 1996; 135: 581-5.
35 Tosti A, Guidetti MS, Bardazzi F et al. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol 1996; 35: 199-201.
36 Tosti A, Guerra L, Bardazzi F. Contact urticaria during topical immunotherapy. Contact Dermatitis 1989; 21: 196-7.
37 Alam M, Gross EA, Savin RC. Severe urticarial reaction to diphenylcyclopropenone therapy for alopecia areata. J Am Acad Dermatol 1999; 40: 110-12.
38 Henderson CA, Ilchyshyn A. Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis. Br J Dermatol 1995; 133: 496-7 (Letter).
39 MacDonald Hull SP, Norris JF, Cotterill JA. Vitiligo following sensitisation with diphencyprone. Br J Dermatol 1989; 120: 232.
40 Claudy AL, Gagnaire D. PUVA treatment of alopecia areata. Arch Dermatol 1983; 119: 975-8.
41 Lassus A, Eskelinen A, Johansson E. Treatment of alopecia areata with three different PUVA modalities. Photodermatology 1984; 1: 141-4.
42 Mitchell AJ, Douglass MC. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol 1985; 12: 644-9.
43 van der Schaar WW, Sillevis SJ. An evaluation of PUVA-therapy for alopecia areata. Dermatologica 1984; 168: 250-2.
44 Taylor CR, Hawk JL. PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years' experience at St John's Institute of Dermatology. Br J Dermatol 1995; 133: 914-18.
45 Healy E, Rogers S. PUVA treatment for alopecia areata-does it work? A retrospective review of 102 cases. Br J Dermatol 1993; 129: 42-4.
46 Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. Br Med J 1983; 287: 1015-17.
47 Vestey JP, Savin JA. A trial of 1% minoxidil used topically for severe alopecia areata. Acta Derm Venereol (Stockh) 1986; 66: 179-80.
48 Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987; 16: 730-6.
49 Ranchoff RE, Bergfeld WF, Steck WD et al. Extensive alopecia areata. Results of treatment with 3% topical minoxidil. Cleve Clin J Med 1989; 56: 149-54.
50 Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol 1987; 16: 745-8.
51 Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987; 123: 1491-3.
52 Nelson DA, Spielvogel RL. Anthralin therapy for alopecia areata. Int J Dermatol 1985; 24: 606-7.
53 Schmoeckel C, Weissmann I, Plewig G et al. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979; 115: 1254-5.
54 Gupta AK, Ellis CN, Tellner DC et al. Cyclosporine A in the treatment of severe alopecia areata. Transplant Proc 1988; 20: 105-8.
55 Shapiro J, Lui H, Tron V et al. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol 1997; 36: 114-17.
56 Ead RD. Oral zinc sulphate in alopecia areata-a double blind trial. Br J Dermatol 1981; 104: 483-4.
57 Berth-Jones J, Hutchinson PE. Treatment of alopecia totalis with a combination of inosine pranobex and diphencyprone compared to each treatment alone. Clin Exp Dermatol 1991; 16: 172-5.
58 Hay IC, Jamieson M, Ormerod AD. Randomized trial of aromatherapy. Successful treatment for alopecia areata. Arch Dermatol 1998; 134: 1349-52.
59 Cheesbrough MJ. Wigs. Br Med J 1989; 299: 1455-6.
|
Language: | English.
|
Document Type: | Guidelines.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0007-0963
|
NLM Journal Code: | aw0, 0004041
|
Annotation(s) | |
|
|